Prosus NV
LSE:0A28
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Prosus NV
LSE:0A28
|
NL |
|
B
|
Benitec Biopharma Inc
F:BJ93
|
US |
|
J Sainsbury PLC
LSE:SBRY
|
UK |
|
S
|
Screen Holdings Co Ltd
SWB:DAO
|
JP |
|
A
|
AutoCanada Inc
F:31K
|
CA |
|
Q
|
QBeyond AG
XMUN:QBY
|
DE |
Wall St Price Targets
0A28 Price Targets Summary
Prosus NV
According to Wall Street analysts, the average 1-year price target for 0A28 is 63.818 EUR with a low forecast of 37.1899 EUR and a high forecast of 84.6401 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0A28's stock price target?
Price Target
63.818
EUR
According to Wall Street analysts, the average 1-year price target for 0A28 is 63.818 EUR with a low forecast of 37.1899 EUR and a high forecast of 84.6401 EUR.
What is the Revenue forecast for Prosus NV?
Projected CAGR
9%
Over the last 8 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 4 years is 9%.
What is the Gross Profit forecast for Prosus NV?
Projected CAGR
10%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 22%. The projected CAGR for the next 4 years is 10%.
What is the Operating Income forecast for Prosus NV?
Projected CAGR
55%
The compound annual growth rate for Operating Income over the next 3 years is 55%.
What is the Pre-Tax Income forecast for Prosus NV?
Projected CAGR
14%
Over the last 8 years, the compound annual growth rate for Pre-Tax Income has been 0%. The projected CAGR for the next 2 years is 14%.
What is the Net Income forecast for Prosus NV?
Projected CAGR
2%
Over the last 8 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 4 years is 2%.
